Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Safety and Effectiveness of CGB-500 Topical Ointment With 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial

The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are:

Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis.

Participants will:

Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks.

Keep a diary of when they use the product and complete a form about their symptoms including itching.

Study Overview

• Status: Completed
• Conditions: Atopic Dermatitis (AD)
• Intervention / Treatment: Drug: CGB-500 with 0.5% tofacitinib; Drug: CGB-500 Ointment with 1% tofacitinib; Drug: Vehicle (placebo)

Detailed Description

The primary objectives of this study:

• To evaluate the safety and tolerability of CGB-500 topical ointment with 0.5% and 1% tofacitinib for the treatment of atopic dermatitis (AD)
• To evaluate the effectiveness of CGB-500 topical ointment with 0.5% and 1% tofacitinib for the treatment of AD

Key trial design:

Intervention Model: Parallel-group Population Type: Pediatric and adult participants Control: Vehicle (without tofacitinib) Population Diagnosis or Condition: Atopic dermatitis Active Comparator: N/A Population Age: ≥ 12 years Trial Intervention Assignment Method: Randomization Site Distribution: US multicenter Number of Arms: 3 Blinding: participants and investigational staff (sponsor, investigator, and evaluators) Number of Participants: 160 to 180

Arms and Duration:

Total duration of trial intervention for each participant: 8 weeks Total duration of trial participation for each participant: Approximately 10 weeks, 2 weeks of screening and 8 weeks of treatment

Arms and Duration Description:

All participants will undergo approximately 2 weeks (Day -15 to Day -1) of screening and 8 weeks of treatment and will be randomized in a 1:1:1 ratio to the following treatment arms. The goal is to randomize 60 participants with a minimum of 48 participants in each of the arms.

• CGB-500 Topical Ointment with 0.5% Tofacitinib BID
• CGB-500 Topical Ointment with 1% Tofacitinib BID
• Vehicle for CGB-500 Topical Ointment BID

• Study Type: Interventional
• Enrollment (Actual): 180
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Fremont, California, United States, 94538
      • Center for Dermatology Clinical Research Inc.
    • Manhattan Beach, California, United States, 90266
      • Ablon Skin Institute and Research Center
    • San Diego, California, United States, 92123
      • TCR Medical Corporation
    • Santa Ana, California, United States, 92705
      • Syrentis Clinical Research
  • Florida
    • Doral, Florida, United States, 33126
      • USA and International Research Inc.
    • Fort Lauderdale, Florida, United States, 33308
      • FXM Clinical Research
    • Gables, Florida, United States, 33134
      • Driven Research
    • Miami, Florida, United States, 33175
      • FXM Clinical Research Miami, LLC
    • Miramar, Florida, United States, 33027
      • FXM Clinical Research Miramar, LLC
    • Sweetwater, Florida, United States, 33182
      • Cordova Research Institute
  • Indiana
    • Plainfield, Indiana, United States, 46168
      • The Indiana Clinical Trials Center, PC
  • Massachusetts
    • Brighton, Massachusetts, United States, 02135
      • Metro Boston Clinical Partners
  • Minnesota
    • New Brighton, Minnesota, United States, 55112
      • J&S Studies, Inc.
  • Nevada
    • Las Vegas, Nevada, United States, 89148
      • JDR Dermatology Research
  • Tennessee
    • Nashville, Tennessee, United States, 37215
      • Tennessee Clinical Research Center
  • Texas
    • Austin, Texas, United States, 78759
      • DermResearch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

To be eligible to participate in this trial, an individual must meet all of the following criteria:

1. Outpatient, male or female of any race, 12 years of age or older. Females of childbearing potential (FOBCP) must have a negative urine pregnancy test at Screening and Baseline and practice a reliable method of contraception throughout the trial.
2. Have a clinical diagnosis of atopic dermatitis (AD) for at least 12 months prior to Baseline that has been clinically stable disease for ≥ 3 months at the time of the screening visit and prior to dose administration and is confirmed to be AD according to the criteria of Hanifin and Rajka.
3. Have an IGA (Investigator's Global Assessment) score of 2, 3, or 4 at Screening and Baseline.
4. Have AD lesions/symptoms covering at least 1% but less than 10% of total BSA (excluding scalp, genitalia, palms, and soles) at Screening and Baseline.
5. Have at least 1 "target lesion" that measures approximately 10 cm2 or more at Screening and Baseline. Lesion must be representative of the participant's disease state and not be located on the scalp, genitalia, palms, or soles.
6. In general, good health as determined by medical history and physical examination at the time of screening (investigator discretion).
7. Have peak pruritus numeric rating scale (PPNRS) score of ≥ 4 on the scale 0 to 10 at Screening and Baseline.
8. Be able to follow trial instructions and likely to complete all required visits.
9. Sign the institutional review board (IRB)-approved informed consent form (ICF, which includes HIPAA) and assent prior to any trial-related procedures being performed.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this trial:

1. Females who are pregnant, breastfeeding, intending to be pregnant during the trial, or who do not agree to use an acceptable form of birth control during the trial if of childbearing potential .
2. Immunocompromised individuals as adjudicated by the principal investigator (PI) based on review of medical history.
3. Known hypersensitivity or previous allergic reaction to any constituent of the IP (e.g., tofacitinib or Janus kinase (JAK) inhibitors, essential oils, choline, phosphatidylcholine, glycerol, propylene glycol, polyethylene glycol).
4. Has clinically significant safety labs (hematology, chemistry, and urinalysis) at the Screening visit that, in the opinion of the investigator, would preclude participation in the study or affect proper assessment of the study endpoints
5. Skin infections (e.g., bacterial, fungal or viral) that can interfere with reliable AD assessments.
6. Basal cell carcinoma within 6 months prior to Baseline.
7. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis or presence of Netherton's Syndrome, immunological deficiencies or diseases, HIV, uncontrolled diabetes, malignancy, or serious active or recurrent infection.
8. Known hepatic impairment or disorder and/or ALT and AST >3X ULN at Screening.
9. Has unstable and impaired renal function with an estimated glomerular filtration rate (eGFR) <60 mL/min using Cockcroft-Gault (C-G) equation (eGFR between 60 to <90 mL/minute or higher is acceptable).
10. Use of moderate to strong CYP3A4 and CYP3A5 inhibitors (e.g. ritonavir, clarithromycin, itraconazole, erythromycin, fluconazole, verapamil, ketoconazole, nefazodone, nelfinavir, diltiazem, ciprofloxacin, grapefruit juice) within 4 weeks prior to Baseline.
11. Participants who have previously failed or had an inadequate response to oral, systemic or topical JAK inhibitors, including in a trial or under a prescription for atopic dermatitis (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).

12. Participants who had an adequate response to JAK inhibitors will be excluded if the following are met:

    1. Use within 2 weeks prior to Baseline of topical JAK inhibitors.
    2. Use within 4 weeks prior to Baseline of systemic JAK inhibitors.
13. Use within 14 days prior to Baseline of: 1) systemic antibiotics, 2) calcipotriene or 3) retinoids.
14. Use within 7 days on the treatment area(s) prior to Baseline of: 1) topical antihistamines, 2) topical antibiotics, 3) topical corticosteroids or 4) other topical drug products.

15. Use of the following treatments prior to Baseline:

    1. For 5 half-lives or 12 weeks (whichever is longer) - biologic agents (e.g., dupilumab).
    2. For 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (e.g., mycophenolate or tacrolimus).
    3. For 2 weeks - UVA/UVB therapy, PUVA (psoralen plus ultraviolet) therapy, tanning booths, or non-prescription UV light sources.
    4. For 2 weeks - immunizations and sedating antihistamines unless on long-term stable regimen (nonsedating antihistamines are permitted).
    5. For 2 weeks - use of other topical treatments for atopic dermatitis (other than bland emollients). Diluted sodium hypochlorite "bleach" baths are allowed if they do not exceed 2 baths per week and their frequency remains the same throughout the trial.
16. Uncontrolled systemic disease.
17. Any serious illness or condition(s) that, in the opinion of the PI, would interfere with full participation in the trial, including administration of IP and attending required trial visits; pose a significant risk to the participant; or interfere with interpretation of trial data.
18. Foreseen unprotected and intense/excessive UV exposure during the trial.
19. Scheduled or planned surgical procedures during the trial.
20. Unable or unwilling to comply with any of the trial requirements.
21. Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with trial participation or may interfere with interpretation of trial results or participant compliance and, in the opinion of the PI, makes the participant inappropriate for trial entry.
22. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
23. Employees of the research center or Investigator.
24. Family of members of employees of the research center or Investigator.

25. Participants (e.g. siblings, spouses, relatives, roommates) residing in the same household cannot be enrolled at the same time.

    -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CGB 500 ointment with 0.5% tofacitinib	Drug: CGB-500 with 0.5% tofacitinib; CGB-500 is a proprietary ointment formulation
Experimental: CGB 500 ointment with 1% tofacitinib	Drug: CGB-500 Ointment with 1% tofacitinib; CGB-500 is a proprietary ointment formulation
Placebo Comparator: vehicle ointment	Drug: Vehicle (placebo); placebo ointment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability	• Overall Incidence of safety events tabulated using the current version of the medical dictionary for regulatory activities (MedDRA).	From enrollment to end of study at 8 weeks
evaluate effectiveness	Primary Efficacy Endpoint • Proportion of participants achieving Investigator's Global Assessment (IGA) response of "Clear" (Score 0) or "Almost Clear" (Score 1) with ≥ 2 grade of improvement at Week 8.	From enrollment to end of study at 8 weeks

Collaborators and Investigators

• Sponsor: CAGE Bio Inc.

Study record dates

Study Major Dates

• Study Start (Actual): December 18, 2024
• Primary Completion (Actual): August 30, 2025
• Study Completion (Actual): October 30, 2025

Study Registration Dates

• First Submitted: January 23, 2025
• First Submitted That Met QC Criteria: January 30, 2025
• First Posted (Actual): February 5, 2025

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: March 30, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Phase 2b study, study the safety and effectiveness of CGB-500 topical ointment with 0.5% and 1% tofacitinib,
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Immune System Diseases; Hypersensitivity, Immediate; Hypersensitivity; Skin Diseases; Skin Diseases, Genetic; Skin Diseases, Eczematous; Dermatitis; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Dermatitis, Atopic; Janus Kinase Inhibitors; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; tofacitinib
• Other Study ID Numbers: CGB-500-04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No